Avocado Consumption and Cellular Aging in Breast Cancer Survivors
Launched by INSTITUT INVESTIGACIO SANITARIA PERE VIRGILI · Jul 30, 2025
Trial Information
Current as of November 13, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This study is looking at whether eating one avocado every day can help slow down biological aging in women who have survived breast cancer. Researchers are especially interested in a part of our cells called telomeres, which tend to get shorter as we age and may be linked to health problems. By seeing if avocados affect telomere length, as well as other health markers like inflammation, heart health, and overall wellbeing, the study hopes to understand if adding avocados to the diet could benefit breast cancer survivors.
Women between 40 and 65 years old who had early or mid-stage breast cancer (stages I to III), finished their treatments at least six months ago, and currently eat fewer than two avocados per week may be able to join. Participants will be randomly assigned to either eat one avocado daily or continue their usual diet with fewer avocados for four months. During the study, they’ll have health checks, blood and urine tests, and answer questions about their diet, activity, and how they’re feeling. This study is not yet recruiting, but it aims to provide useful information about diet and healthy aging after breast cancer.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women diagnosed with primary breast cancer in stages I, II or III;
- • 40-65 years old at screening;
- • Cancer treatment (radiotherapy and chemotherapy) completed ≥ 6 months but not more than 5 years at the time of recruitment;
- • Currently consuming less than 2 avocados per week;
- • Signed the informed consent letter.
- Exclusion Criteria:
- • Metastasis;
- • Ductal carcinoma or lobular carcinoma in situ;
- • Breast cancer recurrence;
- • Cancer diagnosis other than breast cancer or non-melanoma skin cancer;
- • Body mass index ≥40kg/m2;
- • Currently pregnant or breastfeeding, or planning pregnancy in the following 6 months;
- • Allergy to latex;
- • Unwilling to consume avocado;
- • Immunodeficiency or HIV-positive status;
- • Alcohol abuse (\>50g/day);
- • Use of plant sterols, mineral supplements, use of fibre supplements, fish oil, or antioxidants;
- • Currently participating in any other randomized controlled trial;
- • Difficulty or impossibility of an adequate follow-up;
- • Inability or unwillingness to give written informed consent or to communicate with study personnel, or illiteracy;
- • Patients with an acute infection or inflammation (e.g., pneumonia) will be allowed to participate in the study 3 months after recovery.
About Institut Investigacio Sanitaria Pere Virgili
Institut d'Investigació Sanitària Pere Virgili (IISPV) is a leading biomedical research institute based in Tarragona, Spain, dedicated to advancing health through innovative research and clinical trials. Affiliated with the University Rovira i Virgili and the Joan XXIII University Hospital, IISPV focuses on translating scientific discoveries into clinical applications to improve patient care. With a multidisciplinary team of researchers and clinicians, the institute emphasizes collaboration and excellence in various fields, including oncology, cardiovascular health, and infectious diseases. IISPV's commitment to fostering research innovation and enhancing healthcare outcomes positions it as a key player in the global scientific community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Reus, Tarragona, Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported